Nov 21, 2022 7:00 am EST RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
Nov 18, 2022 9:20 am EST NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
Nov 7, 2022 4:35 pm EST NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors
Oct 28, 2022 7:00 am EDT NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
Oct 13, 2022 7:00 am EDT NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
Sep 7, 2022 2:00 am EDT NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
Aug 16, 2022 5:00 pm EDT NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
